Objective: To examine the reliability, validity, responsiveness, and minimal important difference of the 4-m gait speed test in acute respiratory distress syndrome survivors. Design: Secondary analyses of data from two longitudinal follow-up studies of acute respiratory distress syndrome survivors. Test-retest and inter-rater reliability, construct validity (convergent, discriminant, and known group), predictive validity, and responsiveness were examined. The minimal important difference was estimated using anchor-and distribution-based approaches. Setting: A national multicenter prospective study (ARDSNet Long-Term Outcome Study) and a multisite prospective study in Baltimore, MD (Improving Care of Acute Lung Injury Patients). Patients: Acute respiratory distress syndrome survivors with 4-m gait speed assessment up to 60 months after acute respiratory distress syndrome (ARDSNet Long-Term Outcome Study, n = 184; Improving Care of Acute Lung Injury Patients, n = 122).
P atients who survive acute respiratory distress syndrome (ARDS) often have long-lasting impairments in physical functioning (1) (2) (3) . Gait speed is an assessment of physical functioning frequently used in other populations, which appear well suited for ARDS survivors because it is quick and simple to conduct and requires minimal equipment and space.
Gait speed is reliable (4) (5) (6) (7) (8) and valid across many populations, including older adults, multiple sclerosis, stroke, hemodialysis, and chronic obstructive pulmonary disease (COPD) patients (6, (9) (10) (11) (12) (13) . Gait speed also predicts important outcomes, including mortality, hospitalization, functional decline, discharge location, falls, and need for services (10, (13) (14) (15) (16) .
Gait speed is one component of the short physical performance battery (SPPB), a well-established, validated set of performance assessments. However, gait speed alone predicts incident disability nearly as well as the entire SPPB (16) . Furthermore, gait speed is recommended for routine assessment as the "sixth vital sign" (17) and for inclusion in interventional studies focused on sarcopenia and frail older adults (18, 19) . Gait speed is also included in one definition of frailty (20) .
Among gait speed tests, the 4-m gait speed test has been recommended to assess locomotion in the National Institutes of Health (NIH) Toolbox (http://www.nihtoolbox.org), an initiative to develop comprehensive standardized sets of functional measures (21) . However, the 4-m gait speed test has not been psychometrically evaluated in ARDS survivors. Furthermore, the minimal important difference (MID), defined as the smallest difference perceivable by patients, has not been determined for this population. The MID is valuable for determining sample size and interpreting differences between treatment groups. Using data from two different multisite studies of ARDS survivors (n = 306), this study investigates the reliability, concurrent construct validity, predictive validity, responsiveness, and MID for the 4-m gait speed test at different time points during the first 5 years of recovery after ARDS.
MATERIALS AND METHODS

Study Design
Secondary analyses were performed using data from two studies: ARDSNet Long-Term Outcome Study (ALTOS) and Improving Care of Acute Lung Injury Patients (ICAP) (3, 22) . ALTOS is a multicenter national study; the details of which have been published previously (22) and are briefly summarized herein. The data used in this analysis include ALTOS subjects recruited from 12 hospitals within five ARDSNet study centers, with 6-and 12-month follow-up occurring between 2008 and 2012 (22) . ALTOS subjects were recruited based on participation in at least one of the three co-enrolling ARDS Network randomized trials Albuterol to Treat Acute Lung Injury (ALTA) (23), Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (EDEN) (24) , and Enteral omega-3 fatty acid, gammalinolenic acid, and antioxidant supplementation in acute lung injury (OMEGA) (25) . The ICAP study is a prospective cohort study evaluating ARDS survivors from four teaching hospitals in Baltimore, MD. Data from the 36-, 48-, and 60-month follow-up, occurring between 2007 and 2012, were included in this analysis (3) .
Patients with at least one 4-m gait speed were included. All studies obtained informed consent from participants and were approved by relevant institutional review boards.
Study Measures
Four-m gait speed, in m/s, is the primary measure for this psychometric study. In ALTOS and ICAP, the test was performed twice at each assessment (26) . As recommended, the fastest speed was used for these analyses (27) , except for test-retest reliability, which used both tests from each assessment. Data for inter-rater reliability were drawn from on-going quality assurance (QA) reviews of research staff conducted in both studies. These reviews involved comparison of the research staff 's gait speed measurements versus an expert trainer's measurements for the test. If multiple QA reviews were conducted for a specific staff member, the most recent review was used to prevent intra-staff clustering across repeated measures.
Well-established measures reflecting important aspects of physical function (PF) were used to assess convergent validity and known-group validity of the 4-m gait speed test. These measures included the following performance-based tests: the 6-minute walk test (6MWT) (28, 29) , manual muscle testing (MMT) of strength using the Medical Research Council sum score (30-32) (range, 0-60, with < 48 indicating "ICU-acquired weakness,") (33) and spirometry (34) (reported as percent predicted value for forced expiratory volume in 1 s [FEV 1 ] using normative values) (35) . Patientreported measures included the PF domain of the Medical Outcomes Study Short-Form 36 quality of life survey version 2 (SF-36) (36), the mobility subscale of the EuroQOL five dimensions 3-level (EQ-5D-3L) quality of life survey (37) , the number of dependencies using Katz's activities of daily living scale (38) and using Lawton's instrumental activities of daily living (39) , and the overall score of the Functional Performance Inventory-Short Form survey (40) .
Well-established patient-reported mental health (MH) measures were used to assess discriminant validity, including the MH domain of the SF-36, anxiety subscales of the Hospital Anxiety and Depression Scale (41) and the EQ-5D-3L, and post-traumatic stress disorder symptom score of the Impact of Event Scale-Revised (42) . Prior reports of the correlation between physical and MH measures have been weak (typically r < 0.3) making them appropriate for assessing discriminant validity (43) (44) (45) .
For evaluating predictive validity, the following outcomes were used: mortality, hospitalization, alive at home status (whether patients were living at home), return to normal activity (including work, school, homemaking, or volunteering as was occurring prior to hospitalization for ARDS), SF-36 PF score, and EQ-5D utility score. Data were patient (or proxy where appropriate) reported. To assess responsiveness, the SF-36 PF score was used.
Statistical Analysis
Reliability. Intraclass correlation (ICC) was used to evaluate test-retest and inter-rater reliability.
Construct Validity. Pearson and Spearman correlations were used to examine convergent and discriminant validity. As a measure of PF, 4-m gait speed is expected to be at least moderately correlated (r > 0.40) with similar physical health outcomes (convergent validity), but to have weak correlations (r < 0.30) with non-physical health outcomes, such as MH (discriminant validity). Furthermore, we expected that the 4-m gait speed's correlation with physical health outcomes would be stronger than with MH outcomes. For known-group construct validity tests, the two-sample independent t test was used to determine whether mean gait speed significantly differed between patient groupings determined based on evaluation for ICU-acquired weakness (MMT strength score < 48/60) and impaired pulmonary function (FEV 1 < 70% predicted). We hypothesized that gait speed would be significantly lower in patients with muscle weakness and impaired pulmonary function.
Predictive Validity. To determine whether 4-m gait speed predicts subsequent outcomes, logistic and linear regression models were used with the previously described outcome variables as dependent variables and the 4-m gait speed (per 0.11 m/s) (11) from an immediately prior timepoint as the independent variable.
Responsiveness. Linear regression was used to test whether change in gait speed differed for participants who improved, declined, or did not change on the SF-36 PF. Based on available data in the two studies, we examined responsiveness for three time periods: 6-12, 36-48, and 48-60 months. We categorized change in the SF-36 PF as "decline" if scores decreased by greater than or equal to 10 points, "no change" if score decreased or increased by less than 10 points, and "improvement" if score increased by greater than or equal to 10 points. The 10-point increment represented 1 sd for the SF-36 PF and has been identified as important change by clinical experts (46) .
Estimating MID. As recommended (47), we used multiple anchor-and distribution-based methods to estimate the MID. Anchors include the SF-36 PF and EQ-5D utility (EQ-5D was multiplied by 100 for easier presentation). These outcomes were chosen as anchors as they represent distinct, but important, health-related quality of life concepts (EQ-5D utility includes physical and mental aspects), have strong convergent validity with 4-m gait speed, and have previously reported MIDs. To estimate an anchor-based MID, we fit a linear regression model at each timepoint with gait speed as the outcome and an anchor measure, either SF-36 PF or EQ-5D utility as the predictor. The β coefficient from this model represents the difference in average gait speed that is equivalent to a one point difference in the anchor measure at the given follow-up. The β coefficient multiplied by the anchor's MID (five points for SF-36 PF and 7.4 for EQ-5D utility, i.e., the MID of 0.074 multiplied by 100) (48, 49) determines the 4-m gait speed MID estimate using that anchor.
For the distribution-based methods, se of measurement and minimal detectable change at the 90% CI for the 4-m gait speed were calculated as in prior studies (47, 50, 51) . The 0.2 and 0.5 sd of 4-m gait speed were calculated to reflect a small and moderate effect size, based on Cohen's criteria (52) .
We conducted analyses separately for each study and for each follow-up to examine whether findings were consistent despite differences in patient characteristics and follow-up timepoint. For greater power and precision, we pooled analyses over follow-up assessments when feasible. For pooled analyses, repeated measures were accounted by computing robust ses for correlation coefficients. ses for regression coefficients in pooled analyses were adjusted using mixed models to account for repeated measures per individual over time (53, 54) For the distribution-based MIDs, pooled variance of the 4-m gait speed was computed by taking the weighted average of the variance estimates at each follow-up, based on the sample size of each follow-up divided by total observations. The square root of the pooled variance was used to estimate pooled se of measurement.
RESULTS
Patient characteristics were generally similar between the ALTOS and ICAP cohorts ( Table 1) . However, ICAP had a higher proportion of black participants than ALTOS and had longer lengths of stay. Mean (sd) walking speed at the time of the initial evaluation (6 mo for ALTOS and 36 mo for ICAP) was the same in both studies at 1.0 m/s (0.3 m/s).
Reliability
The 4-m gait speed test demonstrated excellent reliability. ICCs for test-retest reliability were 0.89-0.99 across both studies and all five follow-ups. ICC for inter-rater reliability, based on 32 pairs of observations, was 0.97 when pooled across both studies.
Construct Validity
Across both studies and all five follow-ups, 69% of the crosssectional correlations of the 4-m gait speed with other physical health measures were greater than 0.40 ( Table 2) . Correlations with MH measures were generally weak, with 86% of correlations, less than 0.30 (Table 2 ). These findings provide evidence of convergent and discriminant validity, respectively.
As hypothesized for the known groups analysis, patients with ICU-acquired weakness (MMT < 48 vs ≥ 48) and impaired pulmonary function (FEV 1 < 70% vs ≥ 70% predicted) had significantly slower gait speed, and results were generally consistent across studies and follow-ups through 60 months (Table 3) .
Predictive Validity
Gait speed significantly predicted future hospitalization and health-related quality of life in both studies (Table 4) . Furthermore, among ICAP participants, gait speed significantly predicted mortality, alive at home status, and return to work or normal activity. The magnitude of the associations across both studies and for each ICAP follow-up timepoint (Table E1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B568) were comparable and in the expected direction although not all were statistically significant.
Responsiveness
Statistically significant increases in gait speed were observed for patients with a more than 10-point increase in the SF-36 PF domain for ICAP participants in pooled analysis and for changes between 48 and 60 months ( Table 5) . Statistically significant declines in gait speed were also observed for patients with more than 10-point decrease for 48 and 60 months. Gait speed increased and declined consistent with improvement or worsening in SF-36 PF among ALTOS participants between 6 and 12 months, but these changes were not statistically significant.
Estimating MID
Anchor-based MID estimates for the 4-m gait speed test were 0.02-0.04 m/s in pooled analyses ( Table 6) . A broader range, 0.03-0.05 m/s, was observed at specific follow-up (Table E2 , Supplemental Digital Content 2, http://links.lww.com/CCM/ B569). Distribution-based MID estimates were generally larger than anchor-based MID estimates. In pooled analyses, se of measurement and 0.2 sd were each 0.06 m/s for both studies. Minimal detectable change 90 was 0.13-0.14 m/s and 0.5 sd was 0.14-0.15 m/s in the two studies. 
DISCUSSION
These analyses of two multisite studies of ARDS survivors demonstrate that the 4-m gait speed test is a reliable, valid, and responsive performance-based measure of physical functioning over 6-to 60-month follow-up. Data analyses support test-retest and inter-rater reliability of the 4-m gait speed test, as well as its concurrent construct validity, with evidence of convergent and discriminant validity and known group validity, across five discrete follow-up time points in two different ARDS studies. In addition, the 4-m gait speed test demonstrated predictive validity for outcomes, including hospitalization and health-related quality of life, and responsiveness consistent with changes in patient-reported physical functioning. Convergence of anchor-based estimates with se of measurement suggested that 0.03-0.06 m/s is a reasonable range for the MID of the 4-m gait speed among ARDS survivors.
The reliability and construct validity of the 4-m gait speed test in ARDS survivors were similar to reports in other populations. In studies of healthy older adults, patients receiving rehabilitation after stroke, and COPD patients (4, 6, 8) , excellent reliability (ICCs = 0.86-0.97) was reported for gait speed tests of different distances. Prior studies in diverse populations have also found evidence of concurrent construct validity (5, 6, 12, 55) . Faster gait speed was positively associated with better physical health for a range of measures and outcomes and healthy subjects had faster gait speed than subjects with health conditions. However, our study also contributed evidence of discriminant validity, finding the expected weaker correlations between gait speed and MH measures, which were often not examined in prior validation studies of the 4-m gait speed test. Furthermore, concurrent validity findings were robust across a wide range of relevant follow-up time points (i.e., 6-60 mo) and across two multisite studies (including one national study), supporting generalizability of these findings to other ARDS survivors across different points in their recovery trajectory.
For the predictive validity analyses in both ARDS study populations, lower odds of mortality and re-hospitalization, higher odds of being alive at home, and better future healthrelated quality of life were all observed with faster gait speed although these relationships were not always statistically significant. Furthermore, pooled and time-specific estimates were consistent in direction and magnitude of association, affirming predictive validity for 4-m gait speed overall and at different time points. Our findings are consistent with those from previous studies. In diverse populations of older adults and hemodialysis patients of all ages, slower walking speed was predictive of mortality, hospitalization, disability, and nursing home placement (10, (13) (14) (15) (16) . Differences in statistical significance between the studies and time points may be due to relatively small sample sizes or the potential influence of unmeasured contextual or patient characteristics affecting survivors' return to work or their home.
The significant associations with re-hospitalization and future quality of life outcomes suggest that the value the 4-m gait speed test may have for clinical practice and research. Comparable predictive associations reported in geriatric samples have prompted calls for gait speed tests, such as the 4-m gait speed, to be assessed as the "sixth vital sign" (17, 20) in clinical encounters and used in risk prediction and developing patient-centered care plans (14, 15, 56) . Similarly, our findings support further evaluation of ARDS survivors with slow gait speed to help identify those who may benefit from additional interventions and to assist in developing individualized care planning to reduce risks of re-hospitalization and poor healthrelated quality of life. The need to target the right population for evaluations of post-intensive care interventions for critical illness survivors have also been noted (57, 58) . The 4-m gait speed test could play a role in future research to help screen for an appropriate sample for clinical trials. Prior studies have reported on the responsiveness of gait speed, including the 4-m gait speed test (11) , to intervention and to longitudinal change (6, (59) (60) (61) . In our study, changes in 4-m gait speed generally parallel changes in patient-reported PF, supporting responsiveness, although the differences in gait speed across change categories were not all statistically significant. Small sample sizes within selected change categories may have contributed to the lack of consistency observed.
As recommended (47) for MID estimation, we used multiple anchor-based and distribution-based approaches and gave greater weight to anchor-based estimates, which were approximately 0.03 m/s. The distribution-based MID estimates, which do not provide direct evidence for the MID and have a supporting role in MID determination (47) , were generally larger. However, the se of measurement and 0.2 sd estimates, at approximately 0.06 m/s, were relatively close to the anchor-based estimates, suggesting that 0.03-0.06 m/s would be a reasonable MID range for the 4-m gait speed test. Interventional studies aiming to detect a change that is larger than the minimum important difference, such as a moderatesized change, may consider a value of approximately 0.15 m/s, which corresponds to both the 0.5 sd moderate effect size and the minimal detectable change estimates.
Studies in other populations, often using sample sizes substantially smaller than the 306 patients included in our study, have reported variable estimates for the MID of the 4-m gait speed test. However, most range between 0.04 and 0.11 m/s, generally consistent with our estimates. Perera et al (9) reported an MID range of 0.04-0.06 m/s using different anchors in a sample of 492 older adults with various health conditions and determined 0.05 m/s to be a small meaningful change. Kon et al (11) reported MID of 0.08 when anchored to self-reported improvement and 0.11 m/s when anchored to the incremental shuttle test among 463 COPD patients. A study in 43 healthy older adults found se of measurement of 0.006-0.008 m/s and minimal detectable change of 0.01-0.02 m/s for the 4-m gait speed test (8) , whereas a range of 0.04-0.10 m/s for habitual gait speed using an approximately 4-m walkway was reported Generalized estimating equations were used to estimate anchor-based minimal important differences (MIDs) in pooled analyses to account for potential correlation due to repeated measurement. For the distribution-based MIDs, pooled variance of the 4-m gait speed was computed by taking the weighted average of the variance estimates at each follow-up, based on sample size of each follow-up divided by total observations. The square root of the pooled variance was used to estimate the se of measurement.
in 92 patients after hip fracture (62 (4) . Both the 6MWT and the 4-m gait speed test demonstrated concurrent construct validity, predictive validity, and responsiveness for ARDS survivors, based on our study and a prior bi-national evaluation of the 6MWT (63) . However, the NIH toolbox (21) categorizes 4-m gait speed as a measure of locomotion and 6MWT as an endurance measure. Researchers specifically interested in locomotion or endurance should consider these distinctions and select their measure accordingly. However, for researchers interested in these tests as proxies for patient-reported function or health-related quality of life, or to predict important future outcomes, the 4-m gait speed may work as well as the 6MWT. Furthermore, the 4-m gait speed test is more feasible than the 6MWT, requiring markedly less space and time to administer (< 2 min for two tests using a 4-m track length vs 6MWT requiring up to 57 min [6 min for each of two tests plus rest periods] and track length of at least 15 m) (64) .
Despite this study's novelty and its strengths associated with combining two different multisite studies and evaluating patients over 6-to 60-month follow-up, this study has several limitations. First, the sample sizes, especially at specific follow-up, are relatively small and may have contributed to the lack of statistical significance for specific evaluation of predictive validity and responsiveness. Due to this concern, given the highly consistent results across time points, we provided pooled analyses whenever feasible, to increase power. Second, anchor-based MID may be determined cross-sectionally or longitudinally (65); our estimates are from cross-sectional, between-group analyses, and thus are more appropriate for group comparisons rather than evaluating within-patient change over time. Finally, our study specifically focused on the 4-m gait speed among ARDS survivors, and these results may not generalize to gait speed assessments using different distances or to other groups of ICU survivors. Furthermore, our data came from ARDS survivors whose characteristics and care may be influenced by their participation in research studies. However, a recent study demonstrated that 5-, 8-, and 10-m distances yielded consistent results for gait speed (66) . Future studies should evaluate this test in other samples of ARDS survivors and other populations of critical illness survivors.
CONCLUSIONS
The 4-m gait speed is a reliable, valid, and responsive measure of physical functioning among ARDS survivors. The MID range of 0.03-0.06 m/s will help to interpret the efficacy of research interventions in this population.
